APA (7th ed.) Citation

HA, K., M, K., N, M., S, S., M, T., J, S., . . . AD, K. (2026). Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response. Frontiers in immunology, 17, 1771887. https://doi.org/10.3389/fimmu.2026.1771887

Chicago Style (17th ed.) Citation

HA, Kerth, et al. "Therapeutic Hepatitis B Vaccine Employing DNA Prime - MVA Boost Scheme Requires Additional Priming with Recombinant HBsAg to Elicit an Adequate Antibody Response." Frontiers in Immunology 17 (2026): 1771887. https://doi.org/10.3389/fimmu.2026.1771887.

MLA (9th ed.) Citation

HA, Kerth, et al. "Therapeutic Hepatitis B Vaccine Employing DNA Prime - MVA Boost Scheme Requires Additional Priming with Recombinant HBsAg to Elicit an Adequate Antibody Response." Frontiers in Immunology, vol. 17, 2026, p. 1771887, https://doi.org/10.3389/fimmu.2026.1771887.